[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628398":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":40,"collaborators":10,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":10,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":10,"maxAge":10,"enrollmentInfo":52,"targetDuration":10,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Patients with aplastic anemia undergoing ATG or ALG treatment",null,[12],"Drug: ATG\u002FALG",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","ATG\u002FALG","Participants will receive ATG\u002FALG according to standard dosing protocols as per clinical guidelines. During treatment, we will monitor and document any adverse reactions, including their type, severity, duration, and any necessary interventions or changes in treatment plan.",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Weiwang Li, PhD","CONTACT","15332132036","liweiwang@ihcams.ac.cn",[26],{"facility":27,"status":28,"city":29,"state":10,"zip":10,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Regenerative Medicine Center and Red Blood Cell Disorders Center","RECRUITING","Tianjin","China","CN",{"type":33,"coordinates":34},"Point",[35,36],117.17667,39.14222,{"lat":36,"lon":35},[39],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Jun Shi","Director of the Red Blood Cell Diseases Center & Director of the Regenerative Medicine Clinic","100628398","adverse-effects-of-atgalg-therapy-in-aplastic-anemia-100628398",false,"NCT07461116","Adverse Effects of ATG\u002FALG Therapy in Aplastic Anemia","A Study on the Dynamics and Grading Criteria Construction of Adverse Reactions to ATG\u002FALG Therapy in Aplastic Anemia","Inclusion Criteria:\n\n* Meet the diagnostic criteria for aplastic anemia (Camitta criteria);\n* Receiving ATG\u002FALG immunosuppressive therapy for the first time;\n\nExclusion Criteria:\n\n* Previously received hematopoietic stem cell transplantation;\n* Aplastic anemia patients receiving ATG\u002FALG as part of transplant conditioning regimen;","ALL",{"count":53,"type":54},200,"ESTIMATED","OBSERVATIONAL","This prospective, single-center, observational cohort study aims to systematically observe and describe the clinical characteristics of adverse reactions in patients with aplastic anemia undergoing ATG (Anti-Thymocyte Globulin) \u002FALG (Anti-Lymphocyte Globulin) treatment, providing a data foundation for the development of relevant management strategies. This study plans to enroll 200 aplastic anemia patients undergoing ATG\u002FALG treatment",[58],"Aplastic Anaemia",[58,16],"2026-03-04",{"date":62,"type":63},"2026-03-10","ACTUAL",{"date":65,"type":63},"2026-02-23",{"date":67,"type":54},"2027-12-31",{"name":5,"class":6},1]